Zydus Lifesciences Ltd
Zydus Lifesciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #54 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
India business is expected to track double-digit growth for the next 2-3 years, driven by innovative brands, GLP-1 launches, and new proprietary drugs (Page 16). The company expects continued strong growth in revenues and earnings driven by multiple business segments including pharmaceuticals, specialty, biosimilars, and vaccines.
From Zydus Lifesciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business is expected to track double-digit growth for the next 2-3 years, driven by innovative brands, GLP-1 launches, and new proprietary drugs (Page 16).
- US business projected to grow despite loss of Revlimid sales; volume growth recorded at 11% with plans to launch 40-45+ products in FY27 including exclusives and biosimilars (Pages 12, 13, 17).
- Specialty and 505(b)(2) product pipeline in the US to contribute significantly alongside biosimilars and the Ranibizumab launch (Page 17).
- International markets expected to continue strong growth (~20% plus) due to focus on branded space and portfolio expansion in emerging markets (Page 11).
2 more points from Zydus Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zydus Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Zydus is investing in scaling up its Bio CDMO business, which will take 2-3 years to become meaningful, with optimism based on progress in clinical and regulatory milestones, especially for BOT, BAL facilities (Page 8).
- Commercialization of the CDMO business is expected to start in the second half of FY27, with revenues ramping up alongside facility qualifications (Page 7-8).
- The recent acquisitions like Amplitude Surgical and Comfort Click are part of strategic investments aiding long-term growth and margin diversification (Page 5).
2 more points from Zydus Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zydus Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Zydus Lifesciences Ltd said on order book & pipeline — free account, 30 seconds.
Zydus Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.6K Cr, net profit ₹1.3K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zydus Lifesci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zydus Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zydus Lifesciences Ltd Q3 FY26 results?
India business is expected to track double-digit growth for the next 2-3 years, driven by innovative brands, GLP-1 launches, and new proprietary drugs (Page 16). The company expects continued strong growth in revenues and earnings driven by multiple business segments including pharmaceuticals, specialty, biosimilars, and vaccines.
What is Zydus Lifesciences Ltd share price analysis?
Zydus Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 23.3 with a market cap of ₹113,237 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesciences Ltd planning capital expenditure?
Zydus is investing in scaling up its Bio CDMO business, which will take 2-3 years to become meaningful, with optimism based on progress in clinical and regulatory milestones, especially for BOT, BAL facilities (Page 8).
Keep Zydus Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.